Literature DB >> 77876

Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy.

M J Daley, H M Gebel, R G Lynch.   

Abstract

The idiotype-specific myeloma transplantation resistance induced in BALB/c mice by immunization with the DNP-binding IgAlambda2 protein produced by plasmacytoma MOPC-315 is ablated by post-immunization thymectomy. Sham-thymectomy has no effect. The ablative effect of thymectomy is observed is observed in mice challenged subcutaneously with MOPC-315 cells either 3 days after thymectomy, or after a rest period of 44 days after thymectomy. These observations suggest that short-lived, thymic-dependent suppressive factors may play a role in the idiotype-specific myeloma graft resistance.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 77876

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Treatment of lymphoid tumors with anti-idiotype antibodies.

Authors:  G T Stevenson; F K Stevenson
Journal:  Springer Semin Immunopathol       Date:  1983

2.  Effects of adult thymectomy on the contact sensitivity skin reaction and the unresponsiveness caused by feeding contact sensitizing agents.

Authors:  M A Perera; G L Asherson
Journal:  Immunology       Date:  1981-08       Impact factor: 7.397

Review 3.  Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?

Authors:  Q Yi; A Osterborg
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

4.  In vitro idiotypic suppression of chronic lymphocytic leukemia lymphocytes secreting monoclonal immunoglobulin M anti-sheep erythrocyte antibody.

Authors:  C A Bona; A S Fauci
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

5.  Generation of T cell clones binding F(ab')2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy.

Authors:  A Osterborg; M Masucci; S Bergenbrant; G Holm; A K Lefvert; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 6.  Therapeutic vaccine for lymphoma.

Authors:  Seung-Tae Lee; Sattva S Neelapu; Larry W Kwak
Journal:  Yonsei Med J       Date:  2007-02-28       Impact factor: 2.759

7.  Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving antiidiotypic antibodies.

Authors:  R C Kennedy; G R Dreesman; J S Butel; R E Lanford
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

8.  Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.

Authors:  Sheeba K Thomas; Soung-Chul Cha; D Lynne Smith; Kun Hwa Kim; Sapna R Parshottam; Sheetal Rao; Michael Popescu; Vincent Y Lee; Sattva S Neelapu; Larry W Kwak
Journal:  BMC Cancer       Date:  2018-02-13       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.